T-cell Based Immunotherapies for Cancer

and Chronic Infectious Diseases



Andy Headshot_new.jpg
Chief Executive Officer
Scientific Co-Founder
President & Chief Operating Officer
Chief Financial Officer & Controller
Chief Medical Officer
Vice President,
Business Development
macdonald headshot.jpg
paige headshot_new.jpg
Vice President,
Regulatory Affairs
Vice President,
Chemistry, Manufacturing
& Controls
Corporate Legal Counsel


Andy Headshot_new.jpg


Ahmed headshot.jpg
strome headshot.jpg

Immunogenicity and Efficacy of an HBV Vaccine with an Intrinsic Checkpoint Inhibitor

Glycoprotein D, a Checkpoint Inhibitor of Early T cell Activation, Improves Immunogenicity

and Efficacy of an HPV-16 Vaccine in Preclinical Studies

Zhang Y and Ertl CJ (2014). The Effect of Adjuvanting Cancer Vaccines with Herpes Simplex Virus Glycoprotein D on Melanoma-Driven CD8+ T Cell Exhaustion. J. Immunol. 193(4): 1836-46.


Lassaro MO, et al. (2011). Active Immunotherapy Combined With Blockade of a Coinhibitory Pathway Achieves Regression of Large Tumor Masses in Cancer-prone Mice. Mol. Ther. 19(9):1727-36.


Diniz MO, et al. (2010). Immune Responses and Therapeutic Antitumor Effects of an Experimental DNA Vaccine Encoding Human Papillomavirus Type 16 Oncoproteins Genetically Fused to Herpesvirus Glycoprotein D. Clin. Vaccine Immunol. 17(10): 1576-83.


DiMenna L, et al. (2010). Augmentation of Primary Influenza A Virus-Specific CD8+ T Cell Responses in Aged Mice through Blockade of an Immunoinhibitory Pathway. J. Immunol. 184: 5475-5484).


Chen H, et al. (2010). Adenovirus-Based Vaccines: Comparison of Vectors from Three Species of Adenoviridae. J. Virol. 84(20): 10522-32.


Lassaro MO, et al. (2008). Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses. Nat. Med. 14(2): 205-212.


Reyes-Sandoval A, et al. (2004). Human Immunodeficiency Virus Type 1-Specific Immune Responses in Primates upon Sequential Immunization with Adenoviral Vaccine Carriers of Human and Simian Serotypes. J. Virol. 78(14): 7392-7399.